US approves radiation-based prostate cancer drug

(AP)—The U.S. Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones.

The FDA said Wednesday it approved the drug, Xofigo from Bayer Pharmaceuticals, for men whose cancer has grown into bone tumors even after receiving medication or surgery to lower testosterone. The hormone spurs growth of .

Regulators approved Xofigo based on a study of 809 men with advanced prostate cancer who received the drug or placebo. Patients taking Xofigo typically lived 14 months compared to 11.2 months for those taking placebo.

Xofigo's side effects include nausea and diarrhea.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA OKs expanded use of prostate cancer drug

Dec 10, 2012

(HealthDay)—The approved use of the drug Zytiga has been expanded to include treatment of men with late-stage, hormone therapy-resistant prostate cancer before they undergo chemotherapy, the U.S. Food ...

FDA approves genetic test for lung cancer drug

May 14, 2013

The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

Recommended for you

Cancer stem cells linked to drug resistance

17 hours ago

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered ...

Unraveling the 'black ribbon' around lung cancer

Apr 17, 2014

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

User comments